IRIS
FABBIANI, MASSIMILIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.228
NA - Nord America 3.785
AS - Asia 610
AF - Africa 44
SA - Sud America 26
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 8.706
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.757
IT - Italia 1.176
IE - Irlanda 780
GB - Regno Unito 752
RU - Federazione Russa 348
SE - Svezia 274
CN - Cina 269
DE - Germania 196
SG - Singapore 194
UA - Ucraina 194
FR - Francia 189
FI - Finlandia 142
VN - Vietnam 42
CI - Costa d'Avorio 41
ES - Italia 37
NL - Olanda 32
IN - India 29
CZ - Repubblica Ceca 23
BE - Belgio 22
CA - Canada 22
BR - Brasile 17
IR - Iran 14
PL - Polonia 14
HK - Hong Kong 10
EU - Europa 7
LT - Lituania 7
TR - Turchia 7
BG - Bulgaria 6
AU - Australia 5
CH - Svizzera 5
MX - Messico 5
PT - Portogallo 5
DK - Danimarca 4
IL - Israele 4
LV - Lettonia 4
MK - Macedonia 4
PH - Filippine 4
RO - Romania 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
CY - Cipro 3
EC - Ecuador 3
HR - Croazia 3
IQ - Iraq 3
AR - Argentina 2
AZ - Azerbaigian 2
CL - Cile 2
EE - Estonia 2
JP - Giappone 2
KG - Kirghizistan 2
KR - Corea 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
QA - Qatar 2
SA - Arabia Saudita 2
TH - Thailandia 2
A1 - Anonimo 1
AL - Albania 1
AM - Armenia 1
AT - Austria 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
EG - Egitto 1
JO - Giordania 1
MA - Marocco 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 8.706
Salva come PNG Salva come JPEG
Città #
Dublin 766
Southend 686
Santa Clara 452
Fairfield 426
Chandler 389
Ashburn 312
Siena 286
Woodbridge 236
Houston 190
Seattle 170
Wilmington 167
Jacksonville 158
Cambridge 149
Singapore 136
Ann Arbor 128
Helsinki 115
Princeton 109
Florence 89
New York 76
Milan 68
Rome 61
Munich 55
Nanjing 47
Abidjan 41
Dong Ket 39
Menlo Park 39
Boardman 34
San Diego 32
Shanghai 32
Málaga 31
Beijing 29
Los Angeles 26
Brussels 22
Fremont 19
Nanchang 19
Shenyang 19
Moscow 18
London 17
Washington 17
Nuremberg 16
San Mateo 16
Brno 15
Brescia 14
Chicago 14
Toronto 13
Aachen 11
Naples 11
Comun Nuovo 10
Frankfurt am Main 10
Hebei 10
Jinan 10
Paris 10
Ufa 10
Hyderabad 9
Livorno 9
Poggibonsi 9
Tianjin 9
Agliana 8
Düsseldorf 8
Hong Kong 8
Monteriggioni 8
Carrara 7
Dallas 7
Figline Valdarno 7
Gdynia 7
Padova 7
Anagni 6
Changsha 6
Espoo 6
Falls Church 6
Guangzhou 6
Jiaxing 6
Kunming 6
Pisa 6
Redwood City 6
Salerno 6
Sofia 6
Verona 6
Amsterdam 5
Bacoli 5
Catania 5
Catanzaro 5
Columbus 5
Grosseto 5
Indore 5
Lanciano 5
Lappeenranta 5
Migliarino 5
Montreal 5
Norwalk 5
Olomouc 5
Piscataway 5
Taizhou 5
Barolo 4
Bergamo 4
Bologna 4
Fiesole 4
Hangzhou 4
Izmir 4
Newark 4
Totale 6.153
Salva come PNG Salva come JPEG
Nome #
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 223
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 206
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 205
Genetic mechanisms of critical illness in COVID-19 205
Peripheral biomarkers' panel for severe COVID-19 patients 197
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 191
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 179
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 164
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 163
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 163
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 161
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 157
Pathogen-sugar interactions revealed by universal saturation transfer analysis 148
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 148
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 147
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 139
Mapping the human genetic architecture of COVID-19 136
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 134
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 132
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 131
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study 130
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 130
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 128
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 128
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 127
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 127
Epidemiological and clinical study of viral respiratory tract infections in children from Italy 124
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 123
A first update on mapping the human genetic architecture of COVID-19 121
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 120
null 114
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 113
Staphylococcus aureus: studio clinico e microbiologico 113
An explainable model of host genetic interactions linked to COVID-19 severity 108
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 107
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 107
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 106
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-Infected Adults 105
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 105
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in virological outcomes over time 104
Retrospective study of tuberculosis in the Province of Siena [Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena] 103
WES profiling of COVID-19 101
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 100
Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing 100
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 99
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 97
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 96
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 95
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 94
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 92
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 86
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 86
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. 85
Clinical and molecular characterization of COVID-19 hospitalized patients 84
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 84
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 78
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 76
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 75
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 73
Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort 71
THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY 71
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 70
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 69
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 64
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 62
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 61
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 60
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 60
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 58
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 56
Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patient 54
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 53
Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients 52
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 50
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants 49
The Model for Early COvid-19 Recognition (MECOR) score: a simple, low cost, and accurate tool to discriminate between COVID-19 and community-acquired pneumonia 49
Whole-genome sequencing reveals host factors underlying critical COVID-19 46
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 45
Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine. 38
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. 36
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 36
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 35
Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features 34
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 28
Fosfomycin as partner drug for systemic infection management. a systematic review of its synergistic properties from in vitro and in vivo studies 25
Successivi booster vaccinali contro SARS-CoV-2: risposta umorale in pazienti sottoposti a trapianto di cuore o di polmone 20
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 17
Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination? 16
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 15
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 14
Colonizzazione da batteri multiresistenti nel trapianto di polmone ed eventi infettivi: studio pilota osservazionale-retrospettivo 13
Is a radiological score needed to define the severity of Nontuberculous mycobacteria lung disease? 13
Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study 12
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 12
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 12
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 11
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very with good immunological condition 11
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability 11
Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV 10
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses 10
Totale 8.902
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.903
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020556 0 0 0 0 0 72 111 137 87 69 27 53
2020/2021961 22 88 53 96 73 84 36 114 94 88 101 112
2021/20221.111 105 100 43 59 67 53 56 59 87 84 150 248
2022/20231.657 100 153 172 198 134 304 115 158 142 59 73 49
2023/20241.498 71 45 167 93 72 343 435 65 15 44 56 92
2024/20252.212 170 175 388 237 927 315 0 0 0 0 0 0
Totale 9.383